BACKGROUND: The TVT-Secur (Ethicon, Somerville, NJ, USA) is a minimally invasive suburethral synthetic sling used in the treatment of female stress urinary incontinence. It claims to cause less postoperative pain and to enable performing in an office setting. However, this may be at the expense of a significant learning curve and a higher early failure rate. AIMS: To assess objectively the success rate of the TVT-Secur procedure in the 'U' configuration at six months. Secondary outcomes focussed on subjective success rates, complications, patient satisfaction and quality-of-life (QOL). METHODS: A prospective observational study was undertaken at two tertiary referral urogynaecology centres. A cohort of 42 consecutive patients with urodynamic stress incontinence who underwent the TVT-Secur procedure in the 'U' configuration between November 2006 and August 2007 were followed up for six months. Three standardised QOL questionnaires were completed preoperatively and at six months. A urogenital history, visual analogue score (VAS) for patient satisfaction, uroflow and urinary stress test were performed at six months. RESULTS: Recruitment was ceased prematurely because of a high number of early failures. Objective and subjective success rates at six months were 58.3% and 51.3% respectively. Complications included urinary tract infections, voiding difficulty, groin discomfort, haematoma, vaginal pain, tape erosion and intra-operative dislodgement of tape. Prevalence of de novo urge incontinence was 10.3%. Only symptom-specific QOL scores improved and only 48.6% indicated a high level satisfaction (VAS > or = 80%) with TVT-Secur. CONCLUSION: On the basis of this limited study, we are hesitant to recommend the 'U' configuration of the TVT-Secur over its more established counterparts, the TVT and TVT-O.
BACKGROUND: The TVT-Secur (Ethicon, Somerville, NJ, USA) is a minimally invasive suburethral synthetic sling used in the treatment of female stress urinary incontinence. It claims to cause less postoperative pain and to enable performing in an office setting. However, this may be at the expense of a significant learning curve and a higher early failure rate. AIMS: To assess objectively the success rate of the TVT-Secur procedure in the 'U' configuration at six months. Secondary outcomes focussed on subjective success rates, complications, patient satisfaction and quality-of-life (QOL). METHODS: A prospective observational study was undertaken at two tertiary referral urogynaecology centres. A cohort of 42 consecutive patients with urodynamic stress incontinence who underwent the TVT-Secur procedure in the 'U' configuration between November 2006 and August 2007 were followed up for six months. Three standardised QOL questionnaires were completed preoperatively and at six months. A urogenital history, visual analogue score (VAS) for patient satisfaction, uroflow and urinary stress test were performed at six months. RESULTS: Recruitment was ceased prematurely because of a high number of early failures. Objective and subjective success rates at six months were 58.3% and 51.3% respectively. Complications included urinary tract infections, voiding difficulty, groin discomfort, haematoma, vaginal pain, tape erosion and intra-operative dislodgement of tape. Prevalence of de novo urge incontinence was 10.3%. Only symptom-specific QOL scores improved and only 48.6% indicated a high level satisfaction (VAS > or = 80%) with TVT-Secur. CONCLUSION: On the basis of this limited study, we are hesitant to recommend the 'U' configuration of the TVT-Secur over its more established counterparts, the TVT and TVT-O.
Authors: Maria Andrada Hamer; Per-Göran Larsson; Pia Teleman; Christina Eten Bergqvist; Jan Persson Journal: Int Urogynecol J Date: 2012-06-16 Impact factor: 2.894
Authors: Jaromir Masata; Kamil Svabik; Karel Zvara; Petra Drahoradova; Rachid El Haddad; Petr Hubka; Alois Martan Journal: Int Urogynecol J Date: 2012-10 Impact factor: 2.894
Authors: Maria Andrada Hamer; Per-Göran Larsson; Pia Teleman; Christina Etén-Bergqvist; Jan Persson Journal: Int Urogynecol J Date: 2011-04-16 Impact factor: 2.894
Authors: Burhan Coskun; Rebecca S Lavelle; Feras Alhalabi; Gary E Lemack; Philippe E Zimmern Journal: Int Urogynecol J Date: 2014-10-23 Impact factor: 2.894
Authors: Lekha S Hota; Katherine Hanaway; Michele R Hacker; Anthony Disciullo; Eman Elkadry; Patricia Dramitinos; Alexander Shapiro; Tanaz Ferzandi; Peter L Rosenblatt Journal: Female Pelvic Med Reconstr Surg Date: 2012 Jan-Feb Impact factor: 2.091